GARETOSMAB
UNII KR9ZSKO5QE

Substance Identification & Data

This profile provides standardized clinical and technical data for Garetosmab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) KR9ZSKO5QE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2097125-54-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
KR9ZSKO5QE
CAS Registry Number
2097125-54-5
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
GARETOSMAB
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C170022
National Cancer Institute reference terminology for clinical and research data.
INN ID
11041
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
EF-04
Identifier assigned by the United States Adopted Names Council.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Garetosmab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

GARETOSMAB

Common Names & Synonyms

GARETOSMAB [INN]
GARETOSMAB [JAN]
GARETOSMAB [USAN]

Systematic Nomenclature

IMMUNOGLOBULIN G4 (234-PROLINE), ANTI-(HUMAN ACTIVIN A) (HUMAN MONOCLONAL REGN2477 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2477 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS ACTIVIN A)HUMAN MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-453) (HOMO SAPIENS VH (IGHV4-59*01 (89%) (IGHD)-IGHJ3*02 (93%)) (8.7.20) (1-126)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(234))) (127-453)) (140-215')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-215') (HOMO SAPIENS V-KAPPA (IGKV3-20*01-IGKJ*01)(7.3.9) (1'-108')-HOMO SAPIENS IGKC*01 (109'-215')), DIMER (232-232'':235-235'')-BISDISULFIDE
IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS INHBA (INHIBIN SUBUNIT BETA A, ACTIVIN A (INHBA HOMODIMER), ACTIVIN AB (INHBA/INHBB DIMER) AND ACTIVIN AC (INHBA/INHBC DIMER)), MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN (1-453) (VH (HOMO SAPIENS IGHV4-59*01 (88.7%)-(IGHD)-IGHJ3*02 (93.3%)) (8.7.20) (1-126)-HOMO SAPIENS IGHG4*01 (CH1 (127-224), HINGE S10>P (234) (225-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (127-453)), (140-215')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-215') (V-KAPPA (HOMO SAPIENS IGKV3-20*01 (100%)-IGKJ1*01 (100%)) (7.3.9) (1'-108')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (154), V (192) (109'-215'))DIMER (232-232'':235-235'')-BISDISULFIDE

Technical Codes

REGN-2477

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus